

IN THE UNITED STATES PATENT AND TRADEMARK
OFFICE

J1003 U.S. PTO

REQUEST FOR FILING
(RULE 53(b)(1))



009099

07/25/01

FOR DESIGN OR UTILITY APPLICATIONS
(DO NOT USE FOR CIPs)

Rule 53(b)(1) PATENT APPLICATION:

Continuation) application under 37 CFR 1.53(b)(1)
 Divisional)
of pending prior application of

Group Art Unit: 1644

Inventor(s): Darrell R. Anderson et al.

Examiner: R. Schwadron

11046 U.S. PTO
09/911703
07/25/01

Parent Appln. No.: 08 | 475,813 | Atty. Dkt. P 0280647 | Client Ref

Series Code 1 Serial No. 1

New M#

Parent Filed: June 7, 1995

This Appln. Filed: July 25, 2001

Title: Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte
Restricted Differentiation Antigen for Treatment of B Cell Lymphoma

Hon. Commissioner of Patents
Washington, DC 20231

Date: July 25, 2001
(Parent Matter No. 0275756)

Sir:

To effect the above-requested filing today:

Attached is a copy (which must be filed) of the prior application, including:

Abstract
 Specification and claims (79 pages) (must be attached)
 Drawings (must be attached if originally filed): 21 sheet(s)/set: 1 set informal; Formal of size A4 11"

1A. Always X one box, only:

(1) Copy of Signed declaration or oath as originally filed in prior application attached
(2) NO declaration or fee is enclosed; therefore, this is a filing under Rule 53(f).

2. This application is hereby filed by less than all of the inventors named in the prior application. Petition is hereby made requesting deletion as inventor(s) of the following who is/are not inventor(s) of the invention being claimed in this application (DELETE THE FOLLOWING INVENTOR(S)):

1. _____ 2. _____
3. _____ 4. _____
5. _____ 6. _____
7. _____ 8. _____

3.5 THE INVENTOR(S) FOR THIS NEW APPLICATION IS(ARE):

1. _____ 2. _____
3. _____ 4. _____
5. _____ 6. _____
7. _____ 8. _____

3. The entire disclosure of the prior application is considered as being part of the disclosure of the accompanying application and is hereby incorporated therein by reference thereto.

4. Priority is claimed under 35 U.S.C. 119/365 based on filing in _____ of _____ (country)

| Application No. | Filing Date | Application No. | Filing Date |
|-----------------|-------------|-----------------|-------------|
| (1) _____ | _____ | (2) _____ | _____ |
| (3) _____ | _____ | (4) _____ | _____ |
| (5) _____ | _____ | (6) _____ | _____ |

a. (No.) Certified copy/copies attached.

b. Certified copy/copies previously filed on _____ in U.S. Application No. _____ / _____, filed on _____

series code ↑ ↑ serial no.

4(a). c. Certified copy/copies filed during International stage of PCT/ _____ / _____ filed _____
 (a) Domestic priority is claimed from PCT/ _____ / _____, filed _____
 (b) Benefit is claimed of Provisional Application No. 60/_____, filed _____

5. Assignee (optional) IDEC Pharmaceuticals Corporation, San Diego, California

6. Attached is the following number of Assignments (including original and all later successive ones by different assignors): _____ and respective new Cover Sheets. (Do NOT file old cover sheets.)

(Assignments in parent must be refiled with new Cover Sheets in this continuing application if you want it/them recorded against the continuing application.)

Please return the recorded Assignment to the undersigned.

The power of attorney in the prior application is to Robin L. Teskin, Registration No. 35,030

(Name and Reg. No.)
whose current address is as in item 8 below.

a. Recognize as associate attorney _____

(Name, Reg. No. and Address)

8. **Address all future communications to Intellectual Property Group
of Pillsbury Winthrop LLP, 1600 Tysons Boulevard, McLean, VA 22102**

9. This application claims benefit of the following prior US application(s), the contents of which are incorporated into this application by this reference:

No. 08/ 475,813 filed June 7, 1995

No. 08/ 149,099 filed November 3, 1993

No. 07/ 978,891 filed November 13, 1992

No. PCT/ _____ / _____ filed _____, which
designated the U.S. and that International Application was was not published under PCT Article 21(2) in English

9(a). See the attached Preliminary Amendment, which amends the first page of the specification to claim benefit of the above listed US application(s)

10. **Small Entity Status →** is Not claimed is claimed (pre-filing confirmation required)

(No.) Small Entity Statement(s) (not essential since 9/8/00) were/are:

filed in above prior application

attached.

11. Petition to extend the life of the above prior application to at least the date hereof

(one box) is being concurrently filed in that prior application (Use Form PAT-111).

(must be) was previously filed in that prior application (Check length of prior extension).

(X'd) is not necessary for copendency (Double check before X'ing this box).

12. **INFORMATION DISCLOSURE STATEMENT:** Attached is Form PTO-1449 listing all of the documents cited by Applicant and the PTO in the parent application(s) relied upon under 35 USC 120 and referenced in item 9 above. Per Rule 98(d) copies of those documents are not required now. Please consider those documents and advise that they have been considered in this new application as by returning a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609..

13. Attached is a Rule 103(a) Petition to Suspend Action.

14. Reserved

FILING FEE

THE FOLLOWING FILING FEE IS BASED ON
->->->CLAIMS AS FILED AND CHANGED BY PRELIMINARY AMENDMENT IN ITEM 14<-<-<-

NOTE: If box 1A2 is X'd, do not pay fees,
but leave lines 15-22 and 27-32 blank.

| | | | Large/Small Entity | Fee Code |
|--|------------|---------------------|--------------------|--------------|
| 15. Basic Filing Fee | | Design Application | \$320/\$160 | 106/26 |
| 16. Basic Filing Fee | | Utility Application | \$710/\$355 | 101/201 |
| 17. Total Effective Claims | minus 20 = | | x \$18/\$9 | +0 |
| 18. Independent Claims | minus 3 = | | x \$80/\$40 | +0 |
| 19. If any proper multiple dependent claim (ignore improper) is present, | | | \$270/\$135 | +0 |
| 20. | | | Subtotal = | \$710 |
| 21. If "petition" box 13 above is X'd, add petition fee. | | \$130 | +0 | 122 |
| 21A. If box 6 above is X'd, add Assignment recording fee | | \$ 40 | +0 | 581 |
| 22. | | | | |
| TOTAL FILING FEE ATTACHED = | | | \$710 | |
| (carry forward to Item 31) | | | | |

23. ATTACHED:

24. See the attached Preliminary Amendment

25. See NONPUBLICATION REQUEST under Rule 213(a) attached (Pat-258)

26.

**ADDITIONAL FEE CALCULATION FOR
PRELIMINARY AMENDMENT
PER BOXES 24/25**

| Claims remaining after amendment | Highest number previously paid for | Present Extra | Additional Fee | File Code |
|---|---|---------------------------------|-------------------|-----------|
| 27. Total Effective Claims * 47 | minus ** 20 | = 27 x \$18/\$9 | = \$ 486 | (103/203) |
| 28. Independent Claims * 7 | minus *** 3 | = 4 x \$80/\$40 | = + 320 | (102/202) |
| 29. If amendment enters proper multiple dependent claim(s) into this application for the first time, add (per application) | | \$270/\$135 | + 0 | (104/204) |
| 30. | | ADDITIONAL FEE | \$ 806 | |
| 31. | | plus FEE from item 22 on page 3 | + 710 | |
| 32. | | TOTAL FEE | \$ 1,516 | |
| 33. *If the entry in this space is less than a entry in the next space, the "Present Extra" result is "0" | | | | |
| 34. **If the "Highest number previously paid for" (see Item 17 above) is less than 20, write "20" in this space | | | | |
| 35. If the "Highest number previously paid for" (see Item 18 above) is less than 3, write "3" in this space | | | | |
| Deposit Account No. 03-3975 Our Order No. 037003 | | 0280647 | | |
| C# | | M# | | |



00909

CHARGE STATEMENT: Upon the filing of a Declaration pursuant to Rule 60(b) or 60(d), the Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This **CHARGE STATEMENT** does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

**Pillsbury Winthrop LLP
Intellectual Property Group**

By Atty: Robin L. Teskin Reg. No. 35,030

Sig: Robin L. Teskin Fax: (703) 905-2500
Atty./Sec RLT/kmh Tel: (703) 905-2200

NOTE No. 1: File this Request in duplicate with 2 postcard receipts (PAT-103) & attachments
NOTE No. 2: Is extension in parent necessary for copendency? **DOUBLE CHECK** Item 11 above.
 If yes, printout Pat-111 and head it in parent.